New drug aims to stop swelling attacks in hereditary angioedema
NCT ID NCT06361537
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 6 times
Summary
This phase 3 study tests an intravenous C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE) to treat acute attacks and prevent attacks before medical procedures. About 124 participants, aged 2 and older, will receive either the drug or a placebo. The main goal is to see how quickly symptoms like swelling improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- C1 esterase inhibitor (C1-INH) concentrate
- What this could lead to
- If successful, this could provide a fast-acting treatment and pre-procedure prevention for acute hereditary angioedema attacks, reducing swelling and pain.
- What could go wrong
- This is a phase 3 trial, but results may not confirm efficacy or safety for all patients. Risks include allergic reactions or lack of symptom relief.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE HEREDITARY ANGIO EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Octapharma Research Site
WITHDRAWNCentennial, Colorado, 80112, United States
-
Octapharma Research Site
WITHDRAWNFarmington Hills, Michigan, 48334, United States
-
Octapharma Research Site
WITHDRAWNToledo, Ohio, 43617, United States
-
Octapharma Research Site
WITHDRAWNTirana, Albania
-
Octapharma Research Site
RECRUITINGRosario, Argentina
-
Octapharma Research Site
RECRUITINGYerevan, Armenia
-
Octapharma Research Site
RECRUITINGSofia, 1431, Bulgaria
-
Octapharma Research Site
NOT_YET_RECRUITINGBangalore, 560017, India
-
Octapharma Research Site
NOT_YET_RECRUITINGPatna, 801507, India
-
Octapharma Research Site
NOT_YET_RECRUITINGMexico City, 06720, Mexico
-
Octapharma Research Site
NOT_YET_RECRUITINGMéxico, Mexico
-
Octapharma Research Site
WITHDRAWNPodgorica, Montenegro
-
Octapharma Research Site
WITHDRAWNCluj-Napoca, 400162, Romania
-
Octapharma Research Site
WITHDRAWNKragujevac, 11221, Serbia
-
Octapharma Research Site
NOT_YET_RECRUITINGAnkara, Turkey (Türkiye)
-
Octapharma Research Site
NOT_YET_RECRUITINGIstanbul, Turkey (Türkiye)
-
Octapharma Research Site
WITHDRAWNIzmir, Turkey (Türkiye)
-
Octapharma Research Site
NOT_YET_RECRUITINGSakarya, Turkey (Türkiye)
-
Octapharma Research Site
RECRUITINGKyiv, 03057, Ukraine
-
Octapharma Research Site
WITHDRAWNLviv, 79010, Ukraine
-
Octapharma Research Site
NOT_YET_RECRUITINGLviv, 79035, Ukraine
-
Octapharma Research Site 5102
NOT_YET_RECRUITINGLima, 15001, Peru
-
Octapharma Research Site 5103
RECRUITINGLima, 15001, Peru
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple pill shield HAE patients from Procedure-Triggered attacks?
- Teens with rare swelling disorder get new drug tested
- New daily pill aims to stop HAE attacks, but trial cut short
- New drug navenibart aims to tame hereditary swelling attacks
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
- New pill shows promise for controlling rare swelling disorder